Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Linical Yönetim

Yönetim kriter kontrolleri 1/4

Linical's CEO'su Kazuhiro Hatano, Jun2005 tarihinde atandı, in görev süresi 19.33 yıldır. şirketin hisselerinin 3.29% doğrudan sahiptir ve bu hisselerin değeri ¥ 296.06M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 15.3 yıl ve 1.3 yıldır.

Anahtar bilgiler

Kazuhiro Hatano

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	19.3yrs
CEO sahipliği	3.3%
Yönetim ortalama görev süresi	15.3yrs
Yönetim Kurulu ortalama görev süresi	1.3yrs

Son yönetim güncellemeleri

Recent updates

There May Be Some Bright Spots In Linical's (TSE:2183) Earnings

May 22

Some Linical Co., Ltd. (TSE:2183) Shareholders Look For Exit As Shares Take 26% Pounding

Mar 08

Linical (TSE:2183) Is Paying Out A Larger Dividend Than Last Year

Feb 26

CEO

Kazuhiro Hatano (59 yo)

19.3yrs

Görev süresi

Mr. Kazuhiro Hatano has been the Chief Executive Officer and Director at Linical Co. Ltd. since June 2005, serves as its Chief Strategy Officer since August 2024, serves as its Chief Commercial Officer and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kazuhiro Hatano	President	19.3yrs	Veri yok	3.29% ¥ 292.3m
Akihiro Takahashi	Chief Financial Officer	17.5yrs	Veri yok	12.11% ¥ 1.1b
Jun Kawai	Chief Administrative Officer	less than a year	Veri yok	2.66% ¥ 236.4m
Shiori Yamaguchi	Chief Compliance Officer	17.3yrs	Veri yok	0.35% ¥ 31.5m
Keigo Tsujimoto	Chief Project Officer	13.3yrs	Veri yok	4.53% ¥ 403.5m
Masaya Miyazaki	Chief Asia Pacific Officer	17.5yrs	Veri yok	2.66% ¥ 236.4m
Clareece West	President & Chief Commercial Officer of Americas & Europe	less than a year	Veri yok	Veri yok
Tracy Goeken	Chief Medical Officer	no data	Veri yok	Veri yok
Satoru Toyota	Executive Officer & Head of Oncology Business Unit (HQ	no data	Veri yok	Veri yok
Tomoko Inomata	Executive Officer & Head of Primary Business Unit (HQ	no data	Veri yok	Veri yok
Jihoon Hwang	President & CEO of Linical Korea	5.8yrs	Veri yok	Veri yok

15.3yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: 2183 'un yönetim ekibi deneyimli ve deneyimlidir ( 15.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kazuhiro Hatano	President	19.3yrs	Veri yok	3.29% ¥ 292.3m
Kyoichi Shimomura	Independent Outside Director	1.3yrs	Veri yok	Veri yok
Eri Sugiyama	Independent Outside Director	1.3yrs	Veri yok	Veri yok
Yoshiaki Nakashima	Independent Outside Director	1.3yrs	Veri yok	Veri yok
Yuichi Murakami	Independent Outside Director	1.3yrs	Veri yok	Veri yok
Yoshimitsu Ando	Independent Outside Director	1.3yrs	Veri yok	Veri yok
Satoko Nishimura	Independent Outside Director	1.3yrs	Veri yok	Veri yok

1.3yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2183 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Linical Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Linical Co., Ltd., Annual General Meeting, Jun 26, 2024

Linical Co., Ltd., Annual General Meeting, Jun 22, 2023

Less than half of directors are independent

Linical Co., Ltd., Annual General Meeting, Jun 23, 2022

No independent directors

Recent updates

Linical Co., Ltd. to Report Q2, 2025 Results on Nov 14, 2024

First quarter 2025 earnings released: JP¥3.63 loss per share (vs JP¥0.13 profit in 1Q 2024)

Investor sentiment deteriorates as stock falls 22%

Now 23% undervalued

Linical Co., Ltd. to Report Q1, 2025 Results on Aug 14, 2024

Now 21% undervalued

There May Be Some Bright Spots In Linical's (TSE:2183) Earnings

Full year 2024 earnings: EPS exceeds analyst expectations

Consensus EPS estimates increase by 96%

Linical Co., Ltd., Annual General Meeting, Jun 26, 2024

Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2025

Consensus EPS estimates have been upgraded.

Linical Co., Ltd. to Report Fiscal Year 2024 Results on May 15, 2024

Upcoming dividend of JP¥15.00 per share

Some Linical Co., Ltd. (TSE:2183) Shareholders Look For Exit As Shares Take 26% Pounding

Linical (TSE:2183) Is Paying Out A Larger Dividend Than Last Year

Third quarter 2024 earnings released: EPS: JP¥3.32 (vs JP¥4.83 in 3Q 2023)

Linical Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024

Consensus EPS estimates fall by 16%

New minor risk - Profit margin trend

Linical Co., Ltd. to Report Q2, 2024 Results on Nov 14, 2023

New minor risk - Market cap size

Consensus EPS estimates fall by 12%

New minor risk - Share price stability

First quarter 2024 earnings released: EPS: JP¥0.13 (vs JP¥3.37 in 1Q 2023)

Linical Co., Ltd. to Report Q1, 2024 Results on Aug 14, 2023

Now 22% undervalued

Investor sentiment improves as stock rises 17%

Full year 2023 earnings: EPS exceeds analyst expectations

Linical Co., Ltd., Annual General Meeting, Jun 22, 2023

Upcoming dividend of JP¥14.00 per share at 2.0% yield

Third quarter 2023 earnings released: EPS: JP¥4.83 (vs JP¥12.04 in 3Q 2022)

Linical Co., Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2023

Linical Co., Ltd. to Report Q3, 2023 Results on Feb 14, 2023

Linical Co., Ltd. Provides Earnings Guidance for the Year Ending March 2023

Price target increased to JP¥1,400

Less than half of directors are independent

Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023

Linical Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: EPS: JP¥3.37 (vs JP¥2.97 in 1Q 2022)

Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Linical Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022

Consensus EPS estimates increase by 15%

Full year 2022 earnings: EPS exceeds analyst expectations

Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023

Linical Co., Ltd., Annual General Meeting, Jun 23, 2022

No independent directors

Consensus forecasts updated

Investor sentiment improved over the past week

Upcoming dividend of JP¥14.00 per share

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Linical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022

Linical Co., Ltd. to Report Q3, 2022 Results on Feb 14, 2022

Second quarter 2022 earnings released: EPS JP¥8.19 (vs JP¥8.24 in 2Q 2021)

First quarter 2022 earnings released: EPS JP¥2.97 (vs JP¥8.81 loss in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS JP¥23.86 (vs JP¥21.34 in FY 2020)

Upcoming dividend of JP¥14.00 per share

Analysts lower EPS estimates to JP¥10.60

Third quarter 2021 earnings released: EPS JP¥7.53 (vs JP¥7.44 in 3Q 2020)

Revenue and earnings miss expectations

Linical Co., Ltd. to Report Q3, 2021 Results on Feb 12, 2021

Investor sentiment improved over the past week

New 90-day low: JP¥690

New 90-day low: JP¥702

Price target lowered to JP¥900

Linical Co., Ltd. to Report Q2, 2021 Results on Nov 13, 2020

Linical Co., Ltd Enters into Service Contract with the Kitasato Institute

CEO

Görev süresi